Assessing Treatment-Selection Markers using a Potential Outcomes Framework

Biometrics

Volumn 68, Issue 3, 2012, Pages 687-696

  Huang, Ying ^a   Gilbert, Peter B ^a,b   Janes, Holly ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Classification accuracy; Constrained maximum likelihood; Monotone treatment effect; Potential outcomes; Sensitivity analysis; Treatment selection marker

Indexed keywords

MAXIMUM LIKELIHOOD ESTIMATION; PATIENT TREATMENT; STATISTICAL MECHANICS; VACCINES;

CLASSIFICATION ACCURACY; CONSTRAINED MAXIMUM LIKELIHOOD; MA XIMUM LIKELIHOODS; MAXIMUM-LIKELIHOOD; MONOTONE TREATMENT EFFECT; POTENTIAL OUTCOMES; SELECTION MARKER; TREATMENT EFFECTS; TREATMENT SELECTION; TREATMENT-SELECTION MARKER;

SENSITIVITY ANALYSIS;

ACCURACY ASSESSMENT; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNITY; MAXIMUM LIKELIHOOD ANALYSIS; NUMERICAL MODEL; RISK FACTOR; SENSITIVITY ANALYSIS; VACCINE; VIRUS;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84866749582     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2011.01722.x     Document Type: Article

References (22)

1. Albain, K. S., Barlow, W. E., Shak, S., Hortobagy, G. N., Livingston, R. B., Yeh, I., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., Sledge, G. W., Winder, E. P., Hudis, C., Ingle, J. N., Perez, E. A., Pritchard, K. I., Shepherd, L., Gralow, J. R., Yoshizawa, C., Allred, D. C., Osborne, C. K., Hayes, D. F., and for the Breast Cancer Intergroup of North America. (2010). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. The Lancet Oncology 11, 55-65.
2. Allegra, C. J., Jessup, M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., and Schilsky, R. L. (2009). American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. Journal of Clinical Oncology 27, 2091-2096.
3. Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., McElrath, M. J., Casimiro, D. R., Gottesdiener, K. M., Chodakewitz, J. R. A., Corey, L., Robertson, M. N., and the Step Study Protocol Team. (2008). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893.
4. Buyse, M. (2007). Towards validation of statistically reliable biomarkers. European Journal of Cancer Supplements 5, 89-95.
5. Freidlin, B. and Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11, 7872-7878.
6. Gilbert, P. (2003). Goodness-of-fit tests for semiparametric biased sampling models with application to AIDS vaccine trials. Journal of Statistical Planning and Inference 118, 51-81.
7. Gilbert, P. B., Bosch, R. J., and Hudgens, M. G. (2003). Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 59, 531-541.
8. Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., and Bast, R. C., Jr. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology 25, 5287-5312.
9. Janes, H., Pepe, M. S., Bossuyt, P. B., and Barlow, W. E. (2011). Measuring the performance of markers for guiding treatment decisions. Annals of Internal Medicine 154, 253-259.
10. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan C. J., Tu, D., Tebbutt, N. C., Simes, J., Chalchal, H., Shapiro, J. D., Robitaille, S., Price, T. J., Sheperd, L., Au, H., Langer, C., Moore, M. J., and Zalcberg, J. R. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine 359, 1757-1765.
11. Lijmer, J. G. and Bossuyt, P. M. (2009). Various randomized designs can be used to evaluate medical tests. Journal of Clinical Epidemiology 62, 364-373.
12. Mandrekar, S. J., Grothey, A., Goetz, M. P., and Sargent, D. J. (2005). Clinical trial designs for prospective validation of biomarkers. American Journal of Pharmacogenomics 5, 317-325.
13. McIntosh, M. W. and Pepe, M. S. (2002). Combining several screening tests: Optimality of the risk score. Biometrics 58, 657-664.
14. Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., Costantino, J. P., Geyer, C. E., Jr., Wickerham, D. L., and Wolmark, N. (2006). Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24, 3726-3734.
15. Qin, J. and Zhang, J. (1997). A goodness-of-fit test for logistic regression models based on case-control data. Biometrika 84, 609-618.
16. Sargent, D. J., Conley, B. A., Allegra, C., and Collette, L. (2005). Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology 23, 2020-2027.
17. Scharfstein, D. O., Rotnitzky, A., and Robins, J. M. (1999). Adjusting for nonignorable drop-out using semiparametric nonresponse models. Journal of the American Statistical Association 94, 1096-1146.
18. Shepherd, B. E., Redman, M. W., and Ankerst, D. P. (2008). Does finasteride affect the severity of prostate cancer? A causal sensitivity analysis. Journal of the American Statistical Association 484, 1392-1404.
19. Simon, R. (2008). The use of genomics in clinical trial design. Clinical Cancer Research 14, 5954-5958.
20. Simon, R. M., Paik, S., and Hayes, D. F. (2009). Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute 21, 1446-1452.
21. Song, X. and Pepe, M. S. (2004). Evaluating markers for selecting a patient's treatment. Biometrics 60, 874-883.
22. Wang, X. and Zhou, H. (2010). Design and inference for cancer biomarker study with an outcome and auxiliary-dependent subsampling. Biometrics 66, 502-511.